Thomas E. Boyd - Concepedia

Author

Thomas E. Boyd

The University of Texas MD Anderson Cancer Center

Also Known As

T. Boyd, T. E. Boyd, Thomas Boyd, Thomas E Boyd, Thomas E. Boyd

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Virginia Mason Memorial Sarah Cannon Cornell University University of California, Los Angeles

About

Thomas E. Boyd is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	1.3K
2	Immunology	10	10	808
3	Health Sciences	6	6	535
4	Cell Biology	1	1	260
5	Gastroenterology	1	1	32

Thomas E. Boyd

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman, Journal of Clinical Oncology	2012	1.1K
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial Peter Hillmen, Tadeusz Robak, Ann Janssens, The Lancet Hematological MalignancyImmunohematologyComplement 1Ofatumumab Versus ChlorambucilLymphoid Neoplasia	2015	337
Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Susan O’Brien, Joseph O. Moore, Thomas E. Boyd, Journal of Clinical Oncology	2007	298
Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer Heather H. Cheng, Colin C. Pritchard, Thomas E. Boyd, European Urology Biallelic InactivationUrologyOncologyGenitourinary CancerMedicine	2015	260
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, The Lancet Haematology Hematological MalignancyOncologyHematologyImmunologyImmune Checkpoint Inhibitor	2019	249
5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Susan O’Brien, Joseph O. Moore, Thomas E. Boyd, Journal of Clinical Oncology	2009	163
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial Rami S. Komrokji, Guillermo Garcia‐Manero, Lionel Adès, The Lancet Haematology Hematological MalignancyBone Marrow FailureHematologyClinical TrialsMyeloid Neoplasia	2018	118
Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911) Peter Hillmen, Tadeusz Robak, Ann Janssens, Blood	2013	85
Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma Nicholas Di Bella, Raymond Taetle, Kathryn S. Kolibaba, Blood	2009	77
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma Tycel Phillips, Paul M. Barr, Steven I. Park, Investigational New Drugs	2018	76

Page 1